{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:26:36Z","timestamp":1789525596795,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116697","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:18:24Z","timestamp":1774372704000},"page":"116697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP)"],"prefix":"10.1016","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-5653","authenticated-orcid":false,"given":"Aziz","family":"Zaanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Palle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-1713","authenticated-orcid":false,"given":"Florence","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilien","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Ben","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-9082","authenticated-orcid":false,"given":"Bruno","family":"Buecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-0423","authenticated-orcid":false,"given":"Olivier","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Durand-Labrunie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadim","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gagniere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7502-7708","authenticated-orcid":false,"given":"Marine","family":"Jary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-9344","authenticated-orcid":false,"given":"Lola-Jade","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":false,"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116697_bib1","first-page":"1583","article-title":"Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)","volume":"55","author":"Veziant","year":"2023","journal-title":"Dig Liver Dis J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.ejca.2026.116697_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.116697_bib3","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/s41591-025-03793-6","article-title":"Global lifetime estimates of expected and preventable gastric cancers across 185 countries","volume":"31","author":"Park","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116697_bib4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/j.gastro.2020.07.049","article-title":"Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older","volume":"159","author":"Shah","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2026.116697_bib5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-021-08261-1","article-title":"Cancer incidence and mortality trends in France over 1990-2018 for solid tumors: the sex gap is narrowing","volume":"21","author":"Defossez","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116697_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib7","unstructured":"Brierley J., Giuliani M., O\u2019Sullivan B., Rous B., Eycken E.V. TNM classification of malignant tumours, 9th Edition. John Wiley Sons Ltd 2025."},{"key":"10.1016\/j.ejca.2026.116697_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0016-5107(90)71180-7","article-title":"Endoscopic ultrasonographic evaluation of patients with biopsy negative gastric linitis plastica","volume":"36","author":"Andriulli","year":"1990","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2026.116697_bib9","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S2666-7568(23)00101-0","article-title":"G8 screening and health-care use in patients with cancer","volume":"4","author":"Bouzan","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.ejca.2026.116697_bib10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1148\/radiol.2373041380","article-title":"T staging of gastric cancer: role of multi-detector row CT","volume":"237","author":"Kumano","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2026.116697_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1148\/radiol.2422051557","article-title":"Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results","volume":"242","author":"Chen","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2026.116697_bib12","first-page":"1315","article-title":"Staging laparoscopy in gastric cancer to detect peritoneal metastases: a systematic review and meta-analysis","volume":"42","author":"Ramos","year":"2016","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.5340","article-title":"18F-fludeoxyglucose-positron emission tomography\/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective dutch cohort study (PLASTIC)","volume":"156","author":"Gertsen","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102890","article-title":"How do I treat dMMR\/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force","volume":"134","author":"de la Fouchardi\u00e8re","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116697_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib17","article-title":"Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated With Tislelizumab","volume":"38","author":"Moehler","year":"2025","journal-title":"Mod Pathol J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.ejca.2026.116697_bib18","article-title":"Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach","volume":"37","author":"Fassan","year":"2024","journal-title":"Mod Pathol J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.ejca.2026.116697_bib19","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1245\/s10434-016-5279-z","article-title":"Early gastric cancer: trends in incidence, management, and survival in a well-defined French population","volume":"23","author":"Chapelle","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/a-2529-5025","volume":"57","author":"Dinis-Ribeiro","year":"2025","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejca.2026.116697_bib21","first-page":"4","article-title":"Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition)","volume":"33","author":"Ono","year":"2021","journal-title":"Dig Endosc J Jpn Gastroenterol Endosc Soc"},{"key":"10.1016\/j.ejca.2026.116697_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00000658-198902000-00005","article-title":"Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study","volume":"209","author":"Gouzi","year":"1989","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib23","first-page":"170","article-title":"Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial","volume":"230","author":"Bozzetti","year":"1999","journal-title":"Ital Gastrointest Tumor Study Group Ann Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJM199903253401202","article-title":"Extended lymph-node dissection for gastric cancer","volume":"340","author":"Bonenkamp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2017.12.019","article-title":"ECCO essential requirements for quality cancer care: oesophageal and gastric cancer","volume":"122","author":"Allum","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2026.116697_bib26","first-page":"1","article-title":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","volume":"24","author":"Japanese Gastric Cancer Association.","year":"2021","journal-title":"Gastric Cancer J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"10.1016\/j.ejca.2026.116697_bib27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","article-title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial","volume":"11","author":"Songun","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib28","first-page":"939","article-title":"Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis","volume":"19","author":"Quan","year":"2016","journal-title":"Gastric Cancer J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"10.1016\/j.ejca.2026.116697_bib29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamasurg.2022.2749","article-title":"Laparoscopic vs OPen Distal Gastrectomy for Locally Advanced Gastric Cancer: 5-year Outcomes of the KLASS-02 randomized clinical trial","volume":"157","author":"Son","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamasurg.2025.4929","article-title":"Laparoscopic vs open distal gastrectomy with D2 lymphadenectomy for clinical T4a gastric cancer: the UMC-UPPERGI-01 randomized clinical trial","volume":"161","author":"Dat","year":"2026","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib31","first-page":"258","article-title":"Open versus minimally invasive total gastrectomy after neoadjuvant chemotherapy: results of a European randomized trial","volume":"24","author":"van der Wielen","year":"2021","journal-title":"Gastric Cancer J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"10.1016\/j.ejca.2026.116697_bib32","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.20.01540","article-title":"Laparoscopic versus open gastrectomy for gastric cancer (LOGICA): a multicenter randomized clinical trial","volume":"39","author":"van der Veen","year":"2021","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/SLA.0000000000004466","article-title":"Assessment of robotic versus laparoscopic distal gastrectomy for gastric cancer: a randomized controlled trial","volume":"273","author":"Lu","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib36","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib38","doi-asserted-by":"crossref","first-page":"S1623","DOI":"10.1016\/j.annonc.2025.09.096","volume":"36","author":"Tabernero","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib39","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2010.534","article-title":"Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis","volume":"303","author":"GASTRIC","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116697_bib40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial\u2606","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib45","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251389741","article-title":"First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma","volume":"17","author":"Marchesi","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib50","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/SLA.0000000000001542","article-title":"Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis","volume":"263","author":"Markar","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.247","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib53","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/gutjnl-2025-336339","article-title":"Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial","volume":"75","author":"Bang","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2026.116697_bib56","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S2468-1253(25)00209-2","article-title":"Endoscopic versus surgical gastroenterostomy for palliation of malignant gastric outlet obstruction (ENDURO): a randomised controlled trial","volume":"10","author":"van de Pavert","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2026.116697_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5230\/jgc.2017.17.e42","article-title":"Clinical outcomes of endoscopic hemostasis for bleeding in patients with unresectable advanced gastric cancer","volume":"17","author":"Song","year":"2017","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.ejca.2026.116697_bib58","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1245\/s10434-012-2687-6","article-title":"Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?","volume":"20","author":"Mariette","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116697_bib59","article-title":"Chemotherapy for advanced gastric cancer","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2026.116697_bib60","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib62","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib63","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(25)00130-5","article-title":"TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial","volume":"26","author":"Zaanan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib64","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib66","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.116697_bib68","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116697_bib69","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib70","article-title":"Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND\/UCLA modified Delphi panel study","volume":"7","author":"Klempner","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA285","article-title":"Zanidatamab + chemotherapy (CT) \u00b1 tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): primary analysis from HERIZON-GEA-01","volume":"44","author":"Elimova","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib73","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib74","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib75","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO-24-02463","article-title":"Phase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer","volume":"43","author":"Kawakami","year":"2025","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib76","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib77","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116697_bib78","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib79","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1634\/theoncologist.2018-0142","article-title":"A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01)","volume":"24","author":"Lee","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116697_bib80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116697_bib81","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib82","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib83","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib84","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib85","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116697_bib86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejca.2026.116697_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib88","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116697_bib89","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/SLA.0000000000000214","article-title":"Vitamin B(12) deficiency after gastrectomy for gastric cancer: an analysis of clinical patterns and risk factors","volume":"258","author":"Hu","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116697_bib90","first-page":"15","article-title":"Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference","volume":"19","author":"Baiocchi","year":"2016","journal-title":"Gastric Cancer J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:22:40Z","timestamp":1779294160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":90,"alternative-id":["S0959804926004776"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116697","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116697"}}